MedTrace Logo

ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects

NCT04307082 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-08-14

No results posted yet for this study

Summary

This is a Phase 1, open-label, single-centre, non-randomised study to evaluate the absorption, distribution, metabolism, and excretion (ADME) of an oral solution of \[14C\]-ibrexafungerp following administration in healthy male subjects.

Each subject will receive a single dose of \[14C\]-ibrexafungerp and will be followed for up to 20 days. During this period total radioactivity will be measured in blood, urine and faeces.

Conditions

Interventions

DRUG

[14C]-Ibrexafungerp

Radio-labeled Ibrexafungerp, single dose.

Sponsors & Collaborators

  • Inncelerex

    collaborator UNKNOWN

  • Scynexis, Inc.

    lead INDUSTRY

Principal Investigators

  • Nkechi Azie, MD · Scynexis, Inc.

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-05
Primary Completion
2020-05-29
Completion
2020-06-30
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04307082 on ClinicalTrials.gov